Oncology Best Practice Documentation



Similar documents
Leukemias and Lymphomas: A primer

Collaboration to collect Autologous transplant outcomes in Lymphoma and Myeloma (CALM) Additional Questionnaire (MED C) INCLUSION CRITERIA CALM STUDY

Non-Hodgkin s Lymphoma

ICD-10 FREQUENTLY ASKED QUESTIONS

MALIGNANT LYMPHOMAS. Dr. Olga Vujovic (Updated August 2010)

NEOPLASMS C00 D49. Presented by Jan Halloran CCS

Local Coverage Article: Drugs and Biologicals - Chemotherapeutic Agents (A52701)

LCD for Erythrocyte Sedimentation Rate (ESR)

CHAPTER 2. Neoplasms (C00-D49) March MVP Health Care, Inc.

Local Coverage Determination (LCD): Immunohistochemistry (L34369)

Lymphoma Diagnosis and Classification

Cord blood Banking Transplant List for One USA Bank - StemCyte

LYMPHOMA. BACHIR ALOBEID, M.D. HEMATOPATHOLOGY DIVISION PATHOLOGY DEPARTMENT Columbia University/ College of Physicians & Surgeons

Malignant Lymphomas and Plasma Cell Myeloma

ICD-10 CM/PCS Tip Sheets. Oncology

Estimated New Cases of Leukemia, Lymphoma, Myeloma 2014

Cancer. 9p21.3 deletion. t(12;21) t(15;17)

Rehabilitation Best Practice Documentation

Hodgkin and Non-Hodgkin Lymphoma Pre-HCT Data

Non Hodgkin Lymphoma:

MEDICAL COVERAGE POLICY

Non-Hodgkin Lymphoma Richard Orlowski, MD


Acute myeloid leukemia (AML)

A 32 year old woman comes to your clinic with neck masses for the last several weeks. Masses are discrete, non matted, firm and rubbery on

Acute Myeloid Leukemia

Myelodysplasia Acute Myeloid Leukemia Chronic Myelogenous Leukemia Non Hodgkin Lymphoma Chronic Lymphocytic Leukemia Plasma Cell (Multiple) Myeloma

General Thoracic Surgery ICD9 to ICD10 Crosswalks. C34.11 Malignant neoplasm of upper lobe, right bronchus or lung

Cutaneous Lymphoma FAST FACTS

Locoregional & advanced esophagus or esophagogastric junction cancer

REPORTABLE NEOPLASMS. Reportable List

Oncology. Objectives. Cancer Nomenclature. Cancer is a disease of the cell Cancer develops when certain cells begin to grow out of control

Bone Marrow Evaluation for Lymphoma. Faizi Ali, MD Hematopathology Fellow William Beaumont Hospital

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL VOLUME I RESPONSE ASSESSMENT LEUKEMIA CHAPTER 11A REVISED: OCTOBER 2015

PROGNOSIS IN ACUTE LYMPHOBLASTIC LEUKEMIA PROGNOSIS IN ACUTE MYELOID LEUKEMIA

Introduction. About 10,500 new cases of acute myelogenous leukemia are diagnosed each

SEER SINQ s. Finalized March 2011

Lymphoma. Measurability of Quality Performance Indicators Version 2.0

Interesting Case Review. Renuka Agrawal, MD Dept. of Pathology City of Hope National Medical Center Duarte, CA

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Jurisdiction Virginia. Retirement Date N/A

Pediatric Oncology for Otolaryngologists

How CanCer becomes critical in the claims

Alpha-fetoprotein

Understanding Non-Hodgkin Lymphoma

Co-pay assistance organizations offering assistance

Stem Cell Transplantation

Guidelines Most Significantly Affected Under ICD-10-CM. May 29, 2013

Understanding. Pancreatic Cancer

Aggressive lymphomas. Michael Crump Princess Margaret Hospital

Behavioral Health Best Practice Documentation

MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS

ACUTE MYELOID LEUKEMIA (AML),

What is a Stem Cell Transplantation?

New Hampshire Childhood Cancer

chronic leukemia lymphoma myeloma differentiated 14 September 1999 Pre- Transformed Ig Surface Surface Secreted Myeloma Major malignant counterpart

PERIPHERAL SMEARS: THE PRIMARY DIAGNOSTIC TOOL PART II IRMA PEREIRA, MT(ASCP)SH

Phone: Fax: M F 8:00 am 9:00 pm ET

B-cell Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

LEUKEMIA/MDS. PLASMA CELL NEOPLASM 0 - Multiple Myeloma 1 - Plasma cell leukemia 2 - Extramedullary plasmacytoma 3 - Solitary plasmacytoma

6/3/2013. Follicular and Other Slow Growing Lymphomas. Stephen Ansell, MD, PhD Mayo Clinic

LCD for Prostate Specific Antigen (PSA)

Emerging New Prognostic Scoring Systems in Myelodysplastic Syndromes 2012

Corporate Medical Policy

Neurological System Best Practice Documentation

Subtypes of AML follow branches of myeloid development, making the FAB classificaoon relaovely simple to understand.

PROTOCOLS FOR TREATMENT OF MALIGNANT LYMPHOMA

Lymphoid Neoplasms. Sylvie Freeman Department of Clinical Immunology, University of Birmingham

SECOND PRIMARY BREAST CANCERS FOLLOWING HAEMATOLOGIC MALIGNANCIES A CASE SERIES STUDY FARAH TANVEER PGY 3 DR.MEIR WETZLER DR.

National Cancer Institute Research on Childhood Cancers. In the United States in 2005, approximately 9,510 children under age 15 will be

Coding for Hematology

Adult Medical-Surgical Nursing H A E M A T O L O G Y M O D U L E : L E U K A E M I A 2

This module consists of four units which will provide the user a basic knowledge of cancer as a disease.

Non-Hodgkin Lymphoma

Lauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?

GRANIX (tbo-filgrastim)

Non-Hodgkin Lymphoma in Queensland An Overview 2012

Mature Lymphoproliferative disorders (2): Mature B-cell Neoplasms. Dr. Douaa Mohammed Sayed

Challenging Diagnosis in Hematopathology

Update in Hematology Oncology Targeted Therapies. Mark Holguin

ICD-10 Specified or Unspecified?

Hairy Cell Leukemia Facts

Myelodysplasia. Dr John Barry

Non-Hodgkin s lymphoma. Univ. Prof. Dr. Werner Linkesch Univ. Klinik Graz

Basics of AML. Acute myeloid leukemia and related myeloid neoplasms: WHO 2008 brings us closer to understanding clinical behavior

CMS Limitations Guide Mammograms and Bone Density Radiology Services

-Examination of key pipeline candidates with in-depth clinical and commercial profiles of Phase III candidates

Pathology ICD-10-CM Coding Tip Sheet Overview of Key Chapter Updates for Pathology and Top 25 codes

Serum Iron Studies CPT Code : Medicare National Coverage Determination Policy

Transcription:

Oncology Best Practice Documentation Click on the desired Diagnoses link or press Enter to view all information. Diagnoses: Solid Tumors Lymphomas Leukemias Myelodysplastic Syndrome Pathology Findings Associated Diagnoses Contact the following for any documentation questions or concerns: CDI: Shannon Menei 302-733-5973 HIMS Coding: Kim Seery 302-733-1113

Solid Tumors Behavior Benign Malignant Metastatic sites should be documented separately to the highest degree of specificity Uncertain behavior Unspecified Nature In Situ Location Affected organ (specify exact anatomical location within the organ) Laterality (if applicable) Overlapping lesions (specify the organs)

Hodgkin s and Non-Hodgkin s Lymphoma Best practice documentation requires the specified type of lymphoma as well as the anatomical location Hodgkin Nodular lymphocyte predominant Nodular sclerosis classical Mixed cellularity classical Lymphocyte-depleted classical Lymphocyte- rich classical Other classical Non-Hodgkin (specify type) Follicular Non-follicular Mature T/NK-cell lymphoma Other and unspecified types of non-hodgkin lymphoma Other specified types of T/NK lymphoma Specified Lymph Nodes Involved

Hodgkin s and Non-Hodgkin s Lymphoma Best practice documentation requires the specified type of lymphoma as well as the anatomical location Specify specific lymph nodes: Head, face & neck Intrathoracic Intra-abdominal Axilla & upper limb Inguinal region and lower limb Intrapelvic Spleen Multiple sites (specify) Extranodal & solid organ sites (specify)

Follicular and Non-Follicular Lymphomas Follicular Lymphomas Type: Grade I Grade II Grade III Grade IIIa Grade IIIb Diffuse follicle center Cutaneous follicle center Other (specify) Non-Follicular Lymphomas Type: Small cell B-cell Mantle cell Diffuse large B-cell Lymphoblastic (diffuse) Burkitt Other (specify) Non-follicular (diffuse), unspecified

T/NK Cell Lymphomas Mature T/NK Cell Lymphomas Type: Mycosis fungoides Sézary disease Peripheral T-cell,not classified Includes: Lennert s lymphoma Mature T-cell,not elsewhere classified Anaplastic large cell lymphoma, ALK- positive Includes: Anaplastic large cell, CD30- positive Anaplastic large cell lymphoma, ALK- negative Cutaneous T-cell lymphoma Other (specify) Other specified types Type: Extranodal Hepatosplenic T-cell Enteropathy- type (intestinal) T-cell Subcutaneous panniculitislike T-cell Blastic NK-cell Angioimmunoblastic T-cell Primary cutaneous CD30- positive T-cell proliferations

Malignant Immunoproliferative Diseases and other B-cell Lymphomas Type: Waldenstrom macroglobulinemia Mac Heavy chain disease Franklin disease Gamma heavy chain disease Mu heavy chain disease Immunoproliferative small intestinal disease (C88.3) Alpha heavy chain disease Mediterranean lymphoma Extranodal marginal zone B-cell lymphoma of mucosaassociated lymphoid tissue (MALT-lymphoma) SALT lymphoma BALT-lymphoma

Lymphomas Documentation Example Insufficient Documentation Best Practice Documentation Patient with metastatic colon CA, admitted for inpatient chemotherapy treatment. Patient with malignant metastatic colon CA stage IV of transverse colon, with known liver mets, admitted for inpatient chemotherapy treatment. No history of tobacco use.

Leukemias Different leukemias (specificity to follow) Lymphoid Myeloid Monocytic Specify status: Not having achieved remission In remission In relapse

Lymphoid Leukemias Type Acute Lymphoblastic (ALL) Prolymphocytic of B-cell type Hairy cell Adult T-cell lymphoma/leukemia (HTLV-1-associated) Prolymphocytic of T-cell type Mature B-cell Burkitt-type Chronic lymphocytic leukemia of B-cell type Other (specify) Remission Status Not having achieved remission In remission In relapse

Myeloid and Monocytic Leukemias Myeloid Leukemia Type: Acute myeloblastic Chronic, BCR/ABL-positive Atypical chronic, BCR/ABLnegative Myeloid sarcoma Acute promyelocytic Acute myelomonocytic Acute myeloid with 11q23- abnormality Acute myeloid with multilineage dysplasia Other (specify) Status: Not having achieved remission In remission In relapse Monocytic Leukemia Type Acute monoblastic/monocytic AML M5 AML M5a AML M5b Chronic Chronic monocytic leukemia CMML-1 CMML-2 CMML with eosinophilia Juvenile Other (specify) Status: Not having achieved remission In remission In relapse

Leukemia Documentation Example Insufficient Documentation Best Practice Documentation Patient with history of AML, admitted with change in mental status. Work up pending. Patient with history of AML, in remission, admitted with change in mental status. Work up pending.

Myelodysplastic Syndromes Specify: Refractory anemia: Without ring sideroblasts With ring sideroblasts With excess of blasts: Blasts 1 (RAEB 1) Blasts 2 (RAEB 2) Unspecified (RAEB NOS) Refractory cytopenia with multilineage dysplasia with multilineage dysplasia and ring sideroblasts Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality

Myelodysplastic Syndromes Documentation Example Insufficient Documentation Best Practice Documentation Patient with myelodysplastic syndrome admitted with SOB, generalized weakness & cytopenias. Consult hematology/ oncology. Patient with myelodysplastic syndrome with excess of blast type 1, admitted with SOB, generalized weakness & pancytopenia due to MDS. Consult hematology/ oncology.

Pathology Findings Pathology known prior to surgery should be documented and reinforced in the operative report and progress notes. Suspected, possible, or likely pathology should be documented based on clinical judgment whenever possible. Pathology findings should be documented in a progress note, consult, or discharge summary as soon as reviewed or made available. When pathology results are available after discharge it is appropriate and compliant to document them in the acute care legal medical record.

Associated Diagnoses Best practice documentation requires you to document any associated diagnoses and document what the underlying cause is due to : Anemia, Neutropenia, Thrombocytopenia, Pancytopenia, due to: Chemotherapy Radiation Malignancy Other specified cause Ascites (specify if malignant) Thrush Cachexia Dysphagia Electrolyte imbalances (specify) Malnutrition (mild, moderate, severe) Mucositis, due to: Drug induced (specify drug) Radiation Antineoplastic therapy

Key Documentation Concepts Identify the specific site of the neoplasm (e.g., tail of pancreas) Include laterality of site if applicable Specify the morphology of the neoplasm as malignant, benign, in situ or uncertain behavior Specify the cell type of the neoplasm (e.g. basal cell, B-cell) Specify the documented sites as primary or as a metastatic site When appropriate specify status: not having achieved remission, in remission or in relapse Clearly document the reason for the encounter as either a complication of the disease process (e.g., neutropenic fever) or as an adverse effect of treatment (e.g., pancytopenia due to chemo)

Take the Extra Step! Document: ALL chronic conditions present and stable but managed. Significance of abnormal tests (i.e.: UTI, electrolytes, echo) Clarify whether diagnoses are ruled in or ruled out Establish cause-and-effect relationships (liking DM to manifestations) Laterality, if applicable Explain the why and because to support medical necessity Any tobacco use, abuse, dependence, history of smoke exposure (e.g., second hand, occupational, etc.)